It would be "impossible" to move 40% of Taiwan's semiconductor capacity to the U.S., the island's top tariff negotiator said, pushing back against recent comments by American officials who called for ... ...

Core Viewpoint - InnoCare Pharma has received approval from the China National Medical Products Administration for the Investigational New Drug application to conduct clinical trials of ICP-538, marking it as the first VAV1 degrader approved for clinical trials in China and the second globally [1][2]. Group 1: Product Overview - ICP-538 is a novel, potent, and highly selective orally administered molecular glue degrader targeting VAV1, aimed at treating autoimmune diseases such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis [2][3]. - The drug induces rapid and efficient degradation of VAV1 protein in a dose-dependent manner, facilitating the formation of a ternary complex between the CRBN E3 ubiquitin ligase and the VAV1 protein [2]. Group 2: Mechanism of Action - Degradation of VAV1 effectively inhibits T-cell proliferation, differentiation, activation, and cytokine release, as well as B-cell activation and cytokine release, leading to anti-inflammatory and immunomodulatory effects [3]. - Preclinical studies indicate that ICP-538 results in significant reductions in cytokines associated with immune-mediated diseases, with no detectable effects on other proteins [3]. Group 3: Company Insights - InnoCare is a commercial stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class and/or best-in-class drugs for cancer and autoimmune diseases with unmet medical needs [4]. - The company has branches in major cities including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [4].

Group 1 - Resolution Minerals has announced a new gold discovery at its Golden Gate South acreage and is progressing towards a NASDAQ listing [4] - Paradigm Biopharmaceuticals is pivoting into the animal care sector, with its osteoarthritis drug candidate currently being tested in oral form on animals [4] - Australian Mines Ltd reported exceptional scandium grades at its Flemington asset, leading to a 9% increase in shares to 1.8 cents per share [4] - New Age Exploration is under a trading halt while anticipating positive drilling results at the Wagyu Gold Project [4] - Dreadnought Resources reported further high-grade gold discoveries at its Mangaroon project [4] - Memphasys received approval from the Australian drug regulator TGA for its Felix technology aimed at the IVF market, resulting in a 27% share price increase, with shares at 0.7 cents per share [4]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of securities of Richtech Robotics Inc. for the period between January 27, 2026, and January 29, 2026, due to alleged misleading statements made by the company [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Richtech Robotics falsely stated it had a collaborative relationship with Microsoft, which was not true, leading to materially false and misleading statements about the company's business and prospects [5]. - Investors who purchased Richtech Robotics securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly. A lead plaintiff must file a motion by April 3, 2026 [3][6]. - It is noted that no class has been certified yet, and investors can choose to remain absent or select their own counsel [7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company. The firm has been consistently ranked among the top for securities class action settlements [4].

Core Insights - The logistics sector has seen significant engagement from investors, particularly in the ASEAN and US markets, highlighting its growth potential and diversification opportunities [1] Investment Focus - The company has diversified its investments across various sectors including banking, telecommunications, logistics, and hotels, indicating a strategic approach to portfolio management [1] - The entry into the US market in 2020 reflects a growing interest in international investment opportunities, particularly in sectors like banks, hotels, and logistics [1] Market Trends - The popularity of insurance companies in the Philippines since 2014 suggests a shift in investment preferences among local investors, moving towards more diversified financial products [1] - The trend of using platforms like Seeking Alpha for analysis indicates a growing reliance on data-driven insights for investment decisions in both the ASEAN and US markets [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Plug Power Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and statements [1]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased Plug Power securities between January 17, 2025, and November 13, 2025, and aims to provide compensation without any out-of-pocket fees through a contingency fee arrangement [2][3]. - Investors wishing to serve as lead plaintiffs must file with the court by April 3, 2026, to represent other class members in the litigation [1][3]. Group 2: Allegations Against Plug Power - The lawsuit claims that Plug Power's defendants made false and misleading statements regarding the likelihood of receiving funds from the U.S. Department of Energy's Loan and the construction of necessary hydrogen production facilities [5]. - It is alleged that these misstatements led to a misrepresentation of the company's potential projects, suggesting a pivot towards less commercially viable projects, which ultimately misled investors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes its experience and success in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors, showcasing its capability in handling such cases [4].

Core Insights - McDonald's Corporation (MCD) is about to report its financial results, and there are sufficient signals to form expectations regarding the outcomes [1] Group 1 - The company is preparing to release its financial results soon, which has generated anticipation among analysts and investors [1] - The analysis emphasizes a mixed approach to investing, combining long-term holdings with tactical sector rotations, indicating a strategic focus on both stability and adaptability in investment choices [1]

BANGKOK (AP) — World shares advanced and Tokyo’s Nikkei 225 share index jumped as much as 5% to a record on Monday after Japanese Prime Minister Sanae Takaichi’s governing party secured a two-thirds supermajority in a parliamentary election. In early European trading, Germany's DAX gained 0.6% to 24,864.59, while the CAC 40 in Paris edged 0.2% higher, to 8,288.06. Britain's FTSE 100 was up 0.3% at 10,399.61. U.S. futures edged higher after the U.S. stock market roared back on Friday as technology stocks ...

Core Viewpoint - The Vanguard Total Stock Market ETF is highlighted as an ideal long-term investment option due to its broad market coverage and ultra-low expense ratio, making it suitable for various investment goals [1][10]. Group 1: ETF Characteristics - The Vanguard Total Stock Market ETF tracks the CRSP US Total Market Index, encompassing approximately 3,500 individual stocks across large, mid, small, and micro-cap categories, providing comprehensive market exposure [4]. - The ETF charges an expense ratio of just 0.03%, positioning it as one of the most cost-effective investment options available [10]. Group 2: Market Performance and Trends - In 2026, the Russell 2000 index, representing small-cap stocks, outperformed the S&P 500 for 14 consecutive trading days, a phenomenon not seen in 30 years, indicating a shift in market dynamics favoring diversification [7]. - The Vanguard Total Stock Market ETF is currently outperforming due to its diverse sector allocation, contrasting with the large-cap universe heavily weighted towards technology stocks [8]. Group 3: Investment Strategy - A more comprehensive portfolio, such as that offered by the Vanguard Total Stock Market ETF, includes around 25% of stocks that are not large caps, allowing for diversification and potential resilience against market fluctuations [6]. - The ETF is recommended as a "set it and forget it" fund, suggesting that long-term investment could yield significant returns with minimal effort [10].

Core Insights - Innovent Biologics has entered into a partnership with Eli Lilly to develop drugs in the fields of immunology and oncology, with an initial payment of $350 million and potential additional payments of up to $8.5 billion [1] Company Summary - The deal signifies a strategic collaboration between Innovent Biologics and Eli Lilly, focusing on the development of innovative therapies in immunology and oncology [1] - The upfront payment of $350 million indicates a strong commitment from Eli Lilly towards the partnership [1] - The total potential value of the deal, reaching up to $8.5 billion, highlights the anticipated significance and potential success of the drug development efforts [1] Industry Summary - The collaboration reflects ongoing trends in the pharmaceutical industry, where partnerships are increasingly common for drug development, particularly in high-demand areas like immunology and oncology [1] - The financial structure of the deal, with substantial upfront and milestone payments, underscores the competitive landscape and the high stakes involved in developing new therapies [1]